trending Market Intelligence /marketintelligence/en/news-insights/trending/iw03gumfhcxdufiormbgvg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

US federal judge dismisses FTC case against Shire unit

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


US federal judge dismisses FTC case against Shire unit

A U.S. federal judge tossed out the U.S. Federal Trade Commission's antitrust lawsuit seeking an injunction against a Shire Plc unit.

U.S. District Judge Richard Andrews said the regulator failed to show Shire ViroPharma Inc. was about to violate a law, a prerequisite for the injunction in this case.

The FTC accused ViroPharma of anti-competitive conduct for seeking to delay the U.S. Food and Drug Administration's approval of a generic version of Vancocin HCl capsules, used to treat bacterial infections in the gastrointestinal tract.

According to the FTC's complaint, ViroPharma submitted 43 filings with the FDA and filed three lawsuits against the U.S. drug agency between 2006 and 2012, which delayed the approval of a cheaper alternative to the medicine.

"I do not think these allegations, without more, plausibly suggest ViroPharma is 'about to violate' any law enforced by the FTC, particularly when the alleged misconduct ceased almost five years before filing of the complaint," the judge said.

Shire acquired ViroPharma in 2014 and had argued that the alleged conduct had occurred in the past.